Home > > > > > Report Detail

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Epidemiology Forecast to 2028

Publisher Name :
Date: 15-Jan-2019
No. of pages: 50
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Epidemiology Forecast, 2028" report provides a comprehensive analysis of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Markets Covered

- United States

- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

- Japan

Study Period: 2016-2028

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology

The epidemiology section covers the historical, current as well as forecasted epidemiology for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders' views are also taken into account to provide a deep understanding of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) outlook. It also includes the explanation of changing trends of epidemiology outlining the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) scenario.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology Segmentation

The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope

- The report covers detailed overview of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns

- It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan

- The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Report assesses the disease risk and burden and highlights the unmet needs

- It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths

- 10 Year Forecast

- 7MM Coverage

- Total Cases in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Key assessments

- Patient Segmentation in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Risk & Burden

- Factors driving growth in a specific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) patient population

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Epidemiology Forecast to 2028

Table of Contents

1. Report Introduction
2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology Overview at a Glance
2.1. Patient Share Distribution of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in 2016
2.2. Patient Share Distribution of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in 2028
3. Disease Background and Overview: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in 7MM
4.3. Total Prevalent/ Incident Patient Population of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in 7MM - By Countries
5. Epidemiology of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
5.1.3. Sub-Type Specific cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) *
5.1.4. Sex- Specific Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) *
5.1.5. Diagnosed Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
5.4.3. Sub-Type Specific cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) *
5.4.4. Sex- Specific Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) *
5.4.5. Diagnosed Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
5.5.3. Sub-Type Specific cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) *
5.5.4. Sex- Specific Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) *
5.5.5. Diagnosed Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
5.6.3. Sub-Type Specific cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) *
5.6.4. Sex- Specific Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) *
5.6.5. Diagnosed Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
5.7.3. Sub-Type Specific cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) *
5.7.4. Sex- Specific Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) *
5.7.5. Diagnosed Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
5.8.3. Sub-Type Specific cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) *
5.8.4. Sex- Specific Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) *
5.8.5. Diagnosed Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
5.9.3. Sub-Type Specific cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) *
5.9.4. Sex- Specific Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) *
5.9.5. Diagnosed Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
6. Unmet Needs of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
*Indication Specific

List of Tables

Table 1: Total Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in 7MM
Table 2: Total Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in United States (2016-2028)*
Table 5: Sex- Specific Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in United States (2016-2028)*
Table 6: Diagnosed Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Germany (2016-2028) *
Table 9: Sex- Specific Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Germany (2016-2028) *
Table 10: Diagnosed Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in France (2016-2028) *
Table 13: Sex- Specific Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in France (2016-2028) *
Table 14: Diagnosed Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Italy (2016-2028) *
Table 17: Sex- Specific Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Italy (2016-2028) *
Table 18: Diagnosed Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Spain (2016-2028) *
Table 21: Sex- Specific Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Spain (2016-2028) *
Table 22: Diagnosed Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in UK (2016-2028) *
Table 25: Sex- Specific Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in UK (2016-2028) *
Table 26: Diagnosed Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Japan (2016-2028) *
Table 29: Sex- Specific Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Japan (2016-2028) *
Table 30: Diagnosed Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Japan (2016-2028)

List of Figures

Figure 1: Total Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in United States (2016-2028)*
Figure 5: Sex- Specific Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in United States (2016-2028)*
Figure 6: Diagnosed Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Germany (2016-2028) *
Figure 9: Sex- Specific Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Germany (2016-2028) *
Figure 10: Diagnosed Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in France (2016-2028) *
Figure 13: Sex- Specific Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in France (2016-2028) *
Figure 14: Diagnosed Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Italy (2016-2028) *
Figure 17: Sex- Specific Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Italy (2016-2028) *
Figure 18: Diagnosed Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Spain (2016-2028) *
Figure 21: Sex- Specific Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Spain (2016-2028) *
Figure 22: Diagnosed Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in UK (2016-2028) *
Figure 25: Sex- Specific Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in UK (2016-2028) *
Figure 26: Diagnosed Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Japan (2016-2028) *
Figure 29: Sex- Specific Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Japan (2016-2028) *
Figure 30: Diagnosed Cases of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Japan (2016-2028)

  • Global CNS Therapeutics Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 03-Oct-2023        Price: US 3380 Onwards        Pages: 101
    Market Overview of Global CNS Therapeutics market: According to our latest research, the global CNS Therapeutics market looks promising in the next 5 years. As of 2022, the global CNS Therapeutics market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. Central nervous system (CNS) disease is a widespread condition in which the brain does not function properly, limiting health and function. The......
  • Global CNS Therapeutics Market Insights, Forecast to 2029
    Published: 11-Aug-2023        Price: US 4900 Onwards        Pages: 117
    Central nervous system (CNS) disease is a broad category of conditions in which the brain does not function as it should, limiting health and the ability to function. The condition may be an inherited metabolic disorder; the result of damage from an infection, a degenerative condition, stroke, a brain tumor or other problem; or arise from unknown or multiple factors. Movement disorders such as Parkinson's disease, dystonia, and essential tremor are central nervous system conditions. What they ha......
  • Central Nervous System Disorders Therapeutics Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application
    Published: 18-Apr-2023        Price: US 3500 Onwards        Pages: 131
    This report describes the global market size of Central Nervous System Disorders Therapeutics from 2018 to 2022 and its CAGR from 2018 to 2022, and also forecasts its market size to the end of 2028 and its CAGR from 2023 to 2028. For geography segment, regional supply, demand, major players, price is presented from 2018 to 2028. This report cover following regions: North America South America Asia & Pacific Europe MEA The key countries for ......
  • Global CNS Therapeutics Market Insights: Impact of COVID-19 and Future Expectations to 2028
    Published: 16-Mar-2023        Price: US 3260 Onwards        Pages: 117
    Central nervous system (CNS) disease is a broad category of conditions in which the brain does not function as it should, limiting health and the ability to function. The condition may be an inherited metabolic disorder; the result of damage from an infection, a degenerative condition, stroke, a brain tumor or other problem; or arise from unknown or multiple factors. Movement disorders such as Parkinson's disease, dystonia, and essential tremor are central nervous system conditions. What they ha......
  • Global CNS Therapeutics Market Research Report 2023
    Published: 06-Feb-2023        Price: US 2900 Onwards        Pages: 103
    Central nervous system (CNS) disease is a broad category of conditions in which the brain does not function as it should, limiting health and the ability to function. The condition may be an inherited metabolic disorder; the result of damage from an infection, a degenerative condition, stroke, a brain tumor or other problem; or arise from unknown or multiple factors. Movement disorders such as Parkinson's disease, dystonia, and essential tremor are central nervous system conditions. What they ha......
  • CNS Therapeutics Market, Global Outlook and Forecast 2023-2029
    Published: 03-Feb-2023        Price: US 3250 Onwards        Pages: 100
    Central nervous system (CNS) disease is a broad category of conditions in which the brain does not function as it should, limiting health and the ability to function. The condition may be an inherited metabolic disorder; the result of damage from an infection, a degenerative condition, stroke, a brain tumor or other problem; or arise from unknown or multiple factors. Movement disorders such as Parkinson's disease, dystonia, and essential tremor are central nervous system conditions. What they ha......
  • Global Central Nervous System Disorders Therapeutics Market Growth (Status and Outlook) 2023-2029
    Published: 02-Feb-2023        Price: US 3660 Onwards        Pages: 88
    Central Nervous System (CNS) disorders are also called as neurological and psychiatric disorders. CNS disorders can affect either the brain or spinal cord, or both. LPI (LP Information)' newest research report, the "Central Nervous System Disorders Therapeutics Industry Forecast" looks at past sales and reviews total world Central Nervous System Disorders Therapeutics sales in 2022, providing a comprehensive analysis by region and market sector of projected Central Nervous System Disorder......
  • Global Central Nervous System Disorders Therapeutics Market Research Report 2023
    Published: 31-Jan-2023        Price: US 2900 Onwards        Pages: 84
    Central Nervous System (CNS) disorders are also called as neurological and psychiatric disorders. CNS disorders can affect either the brain or spinal cord, or both. Highlights The global Central Nervous System Disorders Therapeutics market was valued at US$ 134580 million in 2022 and is anticipated to reach US$ 169200 million by 2029, witnessing a CAGR of 3.9% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating......
  • Central Nervous System Disorders Therapeutics Market, Global Outlook and Forecast 2023-2029
    Published: 31-Jan-2023        Price: US 3250 Onwards        Pages: 69
    Central Nervous System (CNS) disorders are also called as neurological and psychiatric disorders. CNS disorders can affect either the brain or spinal cord, or both. This report aims to provide a comprehensive presentation of the global market for Central Nervous System Disorders Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and ma......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs